237 related articles for article (PubMed ID: 19647470)
21. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement.
Trysberg E; Nylen K; Rosengren LE; Tarkowski A
Arthritis Rheum; 2003 Oct; 48(10):2881-7. PubMed ID: 14558094
[TBL] [Abstract][Full Text] [Related]
22. Glial fibrillary acidic protein and neurofilament in children with cerebral white matter abnormalities.
Kristjánsdóttir R; Uvebrant P; Rosengren L
Neuropediatrics; 2001 Dec; 32(6):307-12. PubMed ID: 11870586
[TBL] [Abstract][Full Text] [Related]
23. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease.
Constantinescu R; Holmberg B; Rosengren L; Corneliusson O; Johnels B; Zetterberg H
Acta Neurol Scand; 2011 Sep; 124(3):206-10. PubMed ID: 21039366
[TBL] [Abstract][Full Text] [Related]
24. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
[TBL] [Abstract][Full Text] [Related]
25. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy.
Petzold A; Thompson EJ; Keir G; Quinn N; Holmberg B; Dizdar N; Wenning GK; Rascol O; Tolosa E; Rosengren L
J Neurol Sci; 2009 Apr; 279(1-2):76-9. PubMed ID: 19195665
[TBL] [Abstract][Full Text] [Related]
27. Neuronal and glial cerebrospinal fluid protein biomarkers are elevated after West Nile virus infection.
Petzold A; Groves M; Leis AA; Scaravilli F; Stokic DS
Muscle Nerve; 2010 Jan; 41(1):42-9. PubMed ID: 19790244
[TBL] [Abstract][Full Text] [Related]
28. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes.
Bech S; Hjermind LE; Salvesen L; Nielsen JE; Heegaard NH; Jørgensen HL; Rosengren L; Blennow K; Zetterberg H; Winge K
Parkinsonism Relat Disord; 2012 Jan; 18(1):69-72. PubMed ID: 21873100
[TBL] [Abstract][Full Text] [Related]
29. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
Juh R; Kim J; Moon D; Choe B; Suh T
Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
[TBL] [Abstract][Full Text] [Related]
30. Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients.
Su W; Chen HB; Li SH; Wu DY
Clin Neurol Neurosurg; 2012 May; 114(4):372-5. PubMed ID: 22206859
[TBL] [Abstract][Full Text] [Related]
31. Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease.
Rizzo G; Martinelli P; Manners D; Scaglione C; Tonon C; Cortelli P; Malucelli E; Capellari S; Testa C; Parchi P; Montagna P; Barbiroli B; Lodi R
Brain; 2008 Oct; 131(Pt 10):2690-700. PubMed ID: 18819991
[TBL] [Abstract][Full Text] [Related]
32. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.
Nicoletti G; Tonon C; Lodi R; Condino F; Manners D; Malucelli E; Morelli M; Novellino F; Paglionico S; Lanza P; Messina D; Barone P; Morgante L; Zappia M; Barbiroli B; Quattrone A
Mov Disord; 2008 Dec; 23(16):2370-6. PubMed ID: 18816803
[TBL] [Abstract][Full Text] [Related]
33. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
Paviour DC; Thornton JS; Lees AJ; Jäger HR
Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
[TBL] [Abstract][Full Text] [Related]
34. Applause sign in Parkinsonian disorders and Huntington's disease.
Wu LJ; Sitburana O; Davidson A; Jankovic J
Mov Disord; 2008 Dec; 23(16):2307-11. PubMed ID: 18972544
[TBL] [Abstract][Full Text] [Related]
35. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.
Holmberg B; Johnels B; Ingvarsson P; Eriksson B; Rosengren L
Parkinsonism Relat Disord; 2001 Sep; 8(1):23-31. PubMed ID: 11472877
[TBL] [Abstract][Full Text] [Related]
36. Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington's disease.
Constantinescu R; Romer M; Oakes D; Rosengren L; Kieburtz K
Parkinsonism Relat Disord; 2009 Mar; 15(3):245-8. PubMed ID: 19056308
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Mult Scler; 2014 Jan; 20(1):43-50. PubMed ID: 23702432
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration.
Gröschel K; Hauser TK; Luft A; Patronas N; Dichgans J; Litvan I; Schulz JB
Neuroimage; 2004 Feb; 21(2):714-24. PubMed ID: 14980574
[TBL] [Abstract][Full Text] [Related]
39. CSF α-synuclein does not differentiate between parkinsonian disorders.
Aerts MB; Esselink RA; Abdo WF; Bloem BR; Verbeek MM
Neurobiol Aging; 2012 Feb; 33(2):430.e1-3. PubMed ID: 21236518
[TBL] [Abstract][Full Text] [Related]
40. Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression.
Song YJ; Halliday GM; Holton JL; Lashley T; O'Sullivan SS; McCann H; Lees AJ; Ozawa T; Williams DR; Lockhart PJ; Revesz TR
J Neuropathol Exp Neurol; 2009 Oct; 68(10):1073-83. PubMed ID: 19918119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
